卒中模拟症比例是否影响卒中溶栓的成本效益
研究构建决策分析模型,评估疑似急性缺血性卒中患者在明确诊断前接受静脉溶栓的成本效益。结果显示,在3小时时间窗内,当卒中模拟症比例超过30%时,溶栓不再具有成本效益;当比例超过75%时,成本-报销比过高。作者建议医院监测卒中模拟症发生率并建立绩效指标。
要点
- 在3小时时间窗内,卒中模拟症比例超过30%时,静脉溶栓不再具有成本效益。
- 卒中模拟症比例超过75%时,溶栓导致成本-报销比过高(>1.5)。
- 作者建议医院监测卒中模拟症发生率并建立绩效指标。
核心结论
- 从两个分析视角确定了卒中模拟症比例的阈值,超过该阈值后溶栓不再具有成本效益。
- 作者建议医院应监测卒中模拟症发生率并建立绩效指标,以防止急性卒中护理成本上升并避免潜在的患者伤害。
研究设计与样本
- 构建决策分析模型,检查各种急诊科溶栓治疗场景。
- 主要变量包括卒中模拟症与真实卒中患者的比例、从症状发作到治疗的时间以及并发症发生率。
- 成本和 reimbursement 率以及缺血性卒中和卒中模拟症患者的预期临床结局来自已发表数据。
- 报告90天增量成本效益比(从医疗保健部门视角)和成本-报销比(从医院层面视角)。
主要发现
- 在3小时时间窗内,随着卒中模拟症比例增加,增量成本效益比增加。
- 卒中模拟症比例超过30%时,溶栓决策不再具有成本效益。
- 卒中模拟症比例超过75%时,溶栓决策导致高成本-报销比。
- 在症状发作后0至90分钟到达的患者与91至180分钟到达的患者结果相似,但在敏感性分析中受阿替普酶成本的显著影响。
关键数值与推荐
- 成本效益定义为愿意支付每获得一个质量调整生命年低于100 000美元。
- 高成本-报销比定义为大于1.5。
- 卒中模拟症比例阈值:超过30%时溶栓不再具有成本效益;超过75%时成本-报销比过高。
临床怎么用
- 作者建议医院应监测卒中模拟症发生率并建立绩效指标,以防止急性卒中护理成本上升并避免潜在的患者伤害。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Differentiating ischemic stroke patients from stroke mimics (SM), nonvascular conditions which simulate stroke, can be challenging in the acute setting. We sought to model the cost-effectiveness of treating suspected acute ischemic stroke patients before a definitive diagnosis could be made. We hypothesized that we would identify threshold proportions of SM among suspected stroke patients arriving to an emergency department above which administration of intravenous thrombolysis was no longer cost-effective. Methods- We constructed a decision-analytic model to examine various emergency department thrombolytic treatment scenarios. The main variables were proportion of SM to true stroke patients, time from symptom onset to treatment, and complication rates. Costs, reimbursement rates, and expected clinical outcomes of ischemic stroke and SM patients were estimated from published data. We report the 90-day incremental cost-effectiveness ratio of administering intravenous thrombolysis compared with no acute treatment from a healthcare sector perspective, as well as the cost-reimbursement ratio from a hospital-level perspective. Cost-effectiveness was defined as a willingness to pay <$100 000 USD per quality adjusted life year gained and high cost-reimbursement ratio was defined as >1.5. Results- There was an increase in incremental cost-effectiveness ratios as the proportion of SM cases increased in the 3-hour time window. The threshold proportion of SM above which the decision to administer thrombolysis was no longer cost-effective was 30%. The threshold proportion of SM above which the decision to administer thrombolysis resulted in high cost-reimbursement ratio was 75%. Results were similar for patients arriving within 0 to 90 minutes of symptom onset as compared with 91 to 180 minutes but were significantly affected by cost of alteplase in sensitivity analyses. Conclusions- We identified thresholds of SM above which thrombolysis was no longer cost-effective from 2 analytic perspectives. Hospitals should monitor SM rates and establish performance metrics to prevent rising acute stroke care costs and avoid potential patient harms.
引用
- Liberman AL, Choi HJ, French DD, et al. Is the Cost-Effectiveness of Stroke Thrombolysis Affected by Proportion of Stroke Mimics? Stroke. 2019. PMID: 30572813. doi:10.1161/STROKEAHA.118.022857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。